|
|
One Boston Scientific Place
Natick, MA 1760-1537 USA
phone:508-650-8000
fax:
|
|
| Symbol |
BSX |
| Exchange |
NYSE |
| Founded |
1960 |
| Employees |
|
|
|
| www.bostonscientific.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Medical devices used in a range of interventional medical specialties. |
|
| Management |
| J. Raymond Elliott, President and Chief Executive Officer; Brian R. Burns, Senior Vice President, Global Quality; Jeffrey D. Capello, Executive Vice President and Chief Financial Officer; Fredericus A. Colen, Executive Vice President and Chief Technology Officer; Joseph M. Fitzgerald Senior Vice President and President of the Endovascular Unit |
| |
|
|
|
|
|
|
|
| Keywords |
| less-invasive medicine, steerable, catheters, intelligent acquisitions, close collaboration |
|
|
|
| Description |
|
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, neurovascular intervention, electrophysiology, vascular surgery, endoscopy, oncology, urology and gynecology. The Company's products are offered for sale by two dedicated business groups, Cardiovascular and Endosurgery. |
|
| Products / Services |
The Cardiovascular organization focuses on products and technologies for use in interventional cardiology, peripheral interventions, vascular surgery, electrophysiology and neurovascular procedures. The Endosurgery organization focuses on products and technologies for use in oncology, endoscopy, urology and gynecology procedures.
|
|
| Technology / Differentiation |
| Boston Scientific is investing in new technologies across all areas of the Company, resulting in a strong and growing patent portfolio. The Company is consistently expanding investment in new technology, which supports our mission of �Delivering What�s Next� in less-invasive therapies. In addition to the Company�s internal investments, Boston Scientific is committed to investing in external, or acquired, R&D through acquisitions and investments in new businesses. Boston Scientific�s rate of investment actually exceeds most of our peers in the medical device industry, and is spread out across all our businesses. |
|
| Market / Customers |
A wide variety of products including the TAXUS-paclitaxel-eluting coronary stent system.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
